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Antitumor Activity of Pembrolizumab in Biomarker-
Unselected Patients With Recurrent and/or Metastatic Head
and Neck Squamous Cell Carcinoma: Results From the
Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger,
Joseph Paul Eder, Barbara Burtness, Se-Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss,
Ravit Geva, Chia-Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled-Filhart, Kumudu Pathiraja,
Jonathan D. Cheng, and Tanguy Y. Seiwert
A B S T R A C T
Purpose
Treatmentwith pembrolizumab, an anti–programmed death-1 antibody, at 10mg/kg administered once
every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) –positive
recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-
012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker
status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported.
Patients and Methods
Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pem-
brolizumab 200 mg intravenously once every 3 weeks. Imaging was performed every 8 weeks.
Primary end points were overall response rate (ORR) per central imaging vendor (Response
Evaluation Criteria in Solid Tumors v1.1) and safety. Secondary end points included progression-free
survival, overall survival, and association of response and PD-L1 expression. Patients who received
one or more doses of pembrolizumab were included in analyses.
Results
Of 132 patients enrolled,median agewas 60 years (range, 25 to 84 years), 83%weremale, and 57%
received two or more lines of therapy for R/M disease. ORR was 18% (95% CI, 12 to 26) by central
imaging vendor and 20% (95% CI, 13 to 28) by investigator review. Median duration of response
was not reached (range, $ 2 to $ 11 months). Six-month progression-free survival and overall
survival rates were 23% and 59%, respectively. By using tumor and immune cells, a statistically
significant increase in ORR was observed for PD-L1–positive versus –negative patients (22% v 4%;
P = .021). Treatment-related adverse events of any grade and grade$ 3 events occurred in 62% and
9% of patients, respectively.
Conclusion
Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and
yielded a clinically meaningful ORR with evidence of durable responses, which supports further
development of this regimen in patients with advanced HNSCC.
J Clin Oncol 34:3838-3845. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC)
is the seventhmost common cancer worldwide.1 In
the United States, it is estimated there will be
approximately 61,760 new cases of HNSCC and
13,190 deaths in 2016.2 Primary risk factors in-
clude tobacco smoking and alcohol consumption.3
Another risk factor for a growing subset of head
and neck cancers is human papillomavirus (HPV)
infection.4 Several differences among smoking- and
alcohol-related versusHPV-associatedHNSCChave
been reported, including different patient char-
acteristics, genomic profiles, and prognoses; for
example, patients with HPV-associated HNSCC
often have better outcomes than those with HPV-
unrelated disease.5
A common first-line treatment regimen for
recurrent and/or metastatic (R/M) HNSCC is the
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combination of cetuximab, platinum, and fluorouracil (EXTREME
regimen), which has demonstrated a median overall survival (OS) of
10 months.6 Although this regimen has shown promising efficacy,
patients who experience disease progression on first-line therapy or
who are platinum refractory are seldom responsive to treatment,
with response rates to second-line therapies—typically methotrexate,
cetuximab, or taxanes—that range from 3% to 13%.4,7
HNSCC is generally associated with deficiencies of the immune
system8,9; patients exhibit impaired natural killer cell activity, poor
antigen-presenting function, low absolute lymphocyte counts,10 and
mutations in genes that regulate inflammation.9,11 In the healthy
immune system, programmed death-1 (PD-1) receptor functions as
an immune checkpoint and is expressed primarily on the surface of
activated CD4+ and CD8+ T cells.12,13 Engagement of PD-1 by either
of its ligands, programmed death-ligand 1 or 2 (PD-L1 or PD-L2)
results in inhibition of T-cell activation and limits the response
to inflammation.14,15 In HNSCC and other solid tumors, tumor-
infiltrating lymphocytes, and especially T helper 1 cells, activate
interferon-mediated signaling and induce expression of PD-L1 on
cells in the tumor environment, which protects tumor cells from
tumor-directed immunity.16,17 Moreover, HNSCC tumor cells are
known to exhibit high levels of PD-L1 expression.17,18 Preclinical
studies indicate that blockade of the PD-1 and PD-L1 interaction
enhances T-cell activation and inhibits tumor growth.16,17,19
Pembrolizumab, a highly selective humanized monoclonal
immunoglobulin G4 antibody that blocks the interaction between
PD-1 and its ligands, has demonstrated antitumor activity in
multiple tumor types.20-23 Support for pembrolizumab in the
treatment of R/MHNSCC has been described in the initial HNSCC
cohort of the KEYNOTE-012 trial, which demonstrated clinical
activity of pembrolizumab 10 mg/kg administered intrave-
nously once every 2 weeks in patients with PD-L1–positive R/M
HNSCC.24 Overall response rate (ORR) to this body weight–
based dosing regimen was 18% (central imaging vendor review),
with responses in 25% of patients who were HPV positive and 14%
in those who were HPV negative. In that study, responses were
durable (median, 53 weeks); median (95% CI) progression-free
survival (PFS) and OS were 2 months (2 to 4 months) and
13 months (5 months to not-reached), respectively.
Recent studies that have used population pharmacoki-
netics and exposure-response models suggest that a lower, fixed
dose of pembrolizumab (200 mg) and a less frequent admin-
istration schedule (once every 3 weeks) may be sufficient for
target engagement and clinical activity.25,26 A fixed-dose reg-
imen confers several advantages over body weight–based dos-
ing, including safety, convenience, reduction of waste, and
adherence. The aim of the current study was to report the safety
and efficacy of a fixed-dose regimen in an all-comer popula-
tion of patients with R/M HNSCC, regardless of PD-L1 or
HPV status, from a larger HNSCC expansion cohort of the
KEYNOTE-012 trial.
PATIENTS AND METHODS
Patients
The study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonization Good
Clinical Practice guidelines, and was approved by relevant regulatory and
independent ethics committees. All patients provided written informed
consent before study entry.
The KEYNOTE-012 trial was a phase Ib, multicenter, non-
randomized, multicohort study of pembrolizumab in patients with ad-
vanced solid tumors. Patients age $ 18 years with histologically or
cytologically confirmed R/M HNSCC, measurable disease per RECIST
(v1.1; Response Evaluation Criteria in Solid Tumors), Eastern Cooperative
Oncology Group performance status of 0 or 1, and adequate organ
function were eligible for enrollment in the expansion cohort. Patients had
to provide an archival tumor sample at screening and newly obtained
tumor biopsies before starting treatment and after 9 weeks of treatment;
there were no eligibility criteria on the basis of biomarker expres-
sion—patients could be PD-L1 positive or negative and have HPV-
associated or non–HPV-associated disease. HPV-associated disease re-
fers to patients with a primary tumor location of the oropharynx who were
considered by the site investigator to be HPV positive. Non–HPV-
associated disease refers to patients with a non–HPV-associated oropha-
ryngeal cancer and all patients with a primary tumor location outside of
the oropharynx. There was no limit to the number of prior therapies;
patients who were treatment naive were allowed. Patients who received
previous treatments that specifically targeted T-cell costimulation or
checkpoint pathways were excluded. Prior systemic immunosuppressive
therapy had to be concluded within 7 days, chemotherapy or targeted
small-molecule therapy within 2 weeks, and anticancer monoclonal an-
tibody therapy within 4 weeks from the start of pembrolizumab. Patients
with additional progressing malignancies, psychiatric or substance abuse
disorders, HIV or active infection, CNS metastases, hepatitis B or C, or
autoimmune disease were excluded.
Study Design
Patients in this cohort received pembrolizumab 200 mg administered
intravenously once every 3 weeks. Treatment continued for 24 months or
until progressive disease (PD), intolerable toxicity, or investigator and/or
patient decision to withdraw. Clinically stable patients with PD could
remain on therapy until PD confirmation by a follow-up scan. Treatment
response was assessed every 8 weeks by using computed tomography or
magnetic resonance imaging. Patients who achieved complete response
(CR) had the option of discontinuing therapy.
Adverse events (AEs) were monitored and graded according to
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0. Treatment was interrupted for grade 3 AEs or severe
drug-related AEs until toxicity resolved to grade 0 to 1. Treatment was
discontinued for grade 4 treatment-related AEs or if grade 3 AEs did not
resolve within 12 weeks of the last treatment dose. Laboratory safety
evaluations were performed within 10 days of the first study treatment and
up to 72 hours before each dose.
The coprimary end points were safety and ORR per RECIST v1.1 by
central imaging vendor review. The proportion of patients who achieved
a CR, partial response (PR), and stable disease was determined. Secondary
end points included ORR (RECIST v1.1 per investigator), PFS, OS, duration
of response (DOR), and the correlation of response and PD-L1 expression.
The all-patients-as-treated population, which was defined as all
patients who received one or more doses of pembrolizumab, was used for
safety and efficacy analyses. An additional analysis of the primary efficacy
end point was also conducted in all patients who received one or more
doses of pembrolizumab, had measurable disease at baseline, and had one
or more postbaseline scan or who discontinued treatment because of PD or
treatment-related AE (full analysis set population).
Biomarker Analysis
PD-L1 expression was retrospectively evaluated by using an im-
munohistochemistry (IHC) assay, an investigational version of the PD-L1
IHC 22C3 pharmDx assay (Dako, Carpinteria, CA) that uses the 22C3
(Merck, Kenilworth, NJ) anti–PD-L1 antibody. This assay was recently
www.jco.org © 2016 by American Society of Clinical Oncology 3839
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approved as the first PD-L1 IHC companion diagnostic for use in non–
small-cell lung cancer (NSCLC) in the United States. The staining protocol
used in this study was as described in the instructions for the approved
commercial assay. The assay was used to determine PD-L1 expression on
newly obtained or archival tumor samples. Two scoring methods were used
to assess expression prevalence. One scoring method determined the
percentage of tumor cells with membranous PD-L1 expression; details are
provided in the scoring instructions for the approved commercial assay for
NSCLC. A second scoring method took into account membranous PD-L1
staining on both tumor and mononuclear inflammatory cells. Both scores
were measured on a scale from 0% to 100%; PD-L1 positivity was pre-
defined as $ 1% using either of the two scoring methods.
Statistical Analysis
With 100 evaluable patients, the study provided . 99% power to
detect a difference of 15 percentage points in ORR under the null hy-
pothesis of ORR = 5% with a type I error rate of 2.5% if the true ORR was
20%. Success for this hypothesis required at least 11 of 100 responses. Per
protocol, the actual number of patients enrolled exceeded the target to
ensure at least 100 evaluable patients.
Exact methods for binomial parameters were used to determine ORR
per RECIST v1.1. Kaplan-Meier statistics were used to estimate PFS, OS,
and DOR. Follow-up duration, which was defined as the time from en-
rollment to death or database cutoff, was calculated for all patients.
Logistic (ORR) or Cox (PFS and OS) proportional hazards regression
one-sided testing was performed to assess the relationship between efficacy
and PD-L1 expression measured by using tumor cells alone and a combi-
nation of tumor and immune cells. These analyses used centrally reviewed
ORR, PFS, and OS.
RESULTS
Patients
In total, 132 patients were enrolled between June 12, 2014, and
October 8, 2014; the cutoff for data accrual was September 1, 2015.
All enrolled patients received one or more doses of pem-
brolizumab—an all-patients-as-treated population—and were
included in safety and efficacy analyses. The full analysis set
population used for the primary efficacy end point included 118
patients (Fig 1). Twenty-eight patients (21%) had HPV-
associated HNSCC and 104 (79%) had non–HPV-associated
disease. Patients were a median of age 60 years (range, 25 to
84 years), and 110 (83%) were male (Table 1). Patients were
heavily pretreated: 57% received two or more prior therapies for
R/M disease. During the study, therapy was discontinued in 106
patients (80%) because of PD (n = 78), an AE (n = 15), physician
or patient decision (n = 8), death (n = 3), need for medication
exclusion (n = 1), and protocol violation (n = 1; Fig 1).
Safety
Median number of days on pembrolizumab was 88 (range, 1
to 411 days). Treatment-related AEs occurred in 82 patients (62%;
Table 2). The most frequently occurring treatment-related AEs of
any grade included fatigue (n = 28), hypothyroidism (n = 14), and
decreased appetite (n = 11). Twelve patients (9%) experienced
a grade 3 or 4 treatment-related AE (Table 2), most commonly
decreased appetite, facial swelling, and pneumonitis, which oc-
curred in 2 patients each. There were no treatment-related deaths.
Eight patients (6%) discontinued treatment because of treatment-
related AEs, and 29 patients (22%) had one or more dose in-
terruptions as a result of an AE. AEs of special interest because of
immune-related etiology, regardless of causality, occurred in 26
patients (20%); most events were of grade 1 or 2 severity. Grade 3
immune-related AEs included pneumonitis (n = 2), diabetes
mellitus (n = 1), decubitus ulcer (n = 1), colitis (n = 1), and drug-
induced liver injury (n = 1); one grade 4 immune-related AE
(diabetic ketoacidosis) occurred. Of these, two patients who
Patients screened (N = 267)
Patients received one or more doses of pembrolizumab
(all-patients-as-treated population; n = 132)
Patients enrolled (n = 132)
Patients received one or more doses of pembrolizumab,
had measurable disease at baseline,
and had one or more postbaseline scan or discontinued
treatment because of PD or a treatment-related AE
(full analysis set population; n = 118)
Patients excluded
   No measurable
   disease at baseline
   Nontreatment-related AE
   Patient withdrew
   Violated protocol
(n = 14)
(n = 9)
(n = 3)
(n = 1)
(n = 1)
Discontinued treatment
PD
AE
Patient withdrew
Patient died
Physician decision
Excluded medication
Violated protocol
(n = 106)
(n = 78)
(n = 15)
(n = 7)
(n = 3)
(n = 1)
(n = 1)
(n = 1)
Fig 1. Consort diagram. Patient disposi-
tion. AE, adverse event; PD, progressive
disease.
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experienced grade 3 pneumonitis, one patient with grade 3 colitis,
and one patient with grade 2 interstitial lung disease had to dis-
continue study treatment.
Efficacy
After a median follow-up duration of 9 months (interquartile
range, 3 to 11 months), ORR in the all-patients-as-treated
population was 18% (95% CI, 12% to 26%) by central imag-
ing vendor review and 20% (95% CI, 13% to 28%) by in-
vestigator review (Table 3). An additional analysis of the
primary end point using the full analysis set population yielded
ORRs of 20% (95% CI, 13% to 29%) and 21% (95% CI, 14% to
29%) by central imaging vendor review and investigator review,
respectively. In the all-patients-as-treated population by central
review, 4 (3%) of 132 patients achieved a CR, 20 (15%) achieved
a PR, 26 (20%) had stable disease, and 61 (46%) experienced
disease progression. The total disease control rate, which was
defined as the sum of CR, PR, and stable disease for$ 6 months,
was 20%. No cases of pseudoprogression were observed in this
cohort. The ORR was 32% (9 of 28 patients) and 14% (15 of 104
patients) among those with HPV-associated and non–HPV-
associated disease, respectively (Table 3). When patients with
non–HPV-associated disease were further evaluated by their
tumor location in the oropharynx, oral cavity, hypopharynx,
and larynx, ORR was 15% (11 of 76 patients). Patients with
non–HPV-associated disease in other locations had an ORR of
14% (4 of 28 patients). A reduction in target lesion size of any
amount was found in 61% of all patients (Fig 2A).
Median time to response was 2 months (range, 2 to
11 months). Observed responses were durable and persisted over
several assessments, with a median DOR that was not reached
(range, $ 2 to $ 11 months) at the data cutoff. At the time of
writing, 26 patients remained on therapy, and 20 (83%) of 24
radiologic responses were ongoing (Fig 2B).
Median PFS was 2 months (95% CI, 2.0 to 2.2 months)
and the PFS rate at 6 months was 23% (Fig 2C). The 6-month
PFS rate in patients with HPV-associated and non–HPV-
associated HNSCC was 37% and 20%, respectively. Median
OS was 8 months (95% CI, 6 to 10 months). The 6-month OS
rate was 59% in all patients (Fig 2D) and 70% and 56% in
patients with HPV-associated and non–HPV-associated dis-
ease, respectively.
Table 1. Baseline Demographic and Patient Characteristics (all-patients-as-
treated population)
Characteristic
All Patients
(N = 132)
Age, median (range), years 60 (25-84)
Male 110 (83)
Race
White 95 (72)
Asian 29 (22)
Other 8 (6)
ECOG performance status
0 38 (29)
1 94 (71)
Smoking status*
Smoked 81 (61)
Never smoked 51 (39)
HPV status
HPV associated 28 (21)
Non–HPV associated 104 (79)
Sum of target lesions at baseline,
median (range), mm†
99 (16-664)
Primary location‡
Oropharynx 60 (45)
Oral cavity 17 (13)
Larynx 16 (12)
Hypopharynx 12 (9)
Nasal cavity 8 (6)
Nasopharynx 5 (4)
Sinus 3 (2)
Other§ 9 (7)
Previous adjuvant and/or neoadjuvant
therapy¶
53 (40)
No. of previous lines of therapy for
recurrent or metastatic disease
0 24 (18)
1 33 (25)
2 27 (21)
3 20 (15)
4 15 (11)
$ 5 13 (10)
NOTE. Data are given as No. (%) unless otherwise stated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HPV, human
papillomavirus.
*Of patients, 17 (61%) with HPV-associated and 64 (62%) with non–HPV-
associated disease smoked; 11 (39%) patients with HPV-associated and
40 (38%) with non–HPV-associated disease never smoked.
†n = 123.
‡Primary tumor location was unknown for two patients.
§Primary location of tumors grouped as “other”were lymph node/neck (n = 3),
lymph node/pharynx (n = 1), pharynx (n = 1), left ear (n = 1), external auditory
canal (n = 1), thyroid (n = 1), and nasal ala (n = 1).
¶All adjuvant/neoadjuvant therapies were chemotherapies.
Table 2. Treatment-Related Adverse Events by Grade Severity (all-patients-as-
treated population; N = 132)
Treatment-Related
Adverse Event
Grade 1 or 2
($ 10%
of patients),
No. (%)
Grade 3
(any occurrence),
No. (%)
Grade 4
(any occurrence),
No. (%)
Patients with $ 1
event
70 (53) 8 (6) 4 (3)
Hypothyroidism 14 (11) 0 0
Immune
thrombocytopenic
purpura
0 0 1 (1)
Abdominal pain 1 (1) 1 (1) 0
Colitis 0 1 (1) 0
Dysphagia 1 (1) 1 (1) 0
Nausea 6 (5) 1 (1) 0
Stomatitis 1 (1) 1 (1) 0
Facial edema 0 1 (1) 0
Fatigue 28 (21) 0 0
Localized edema 0 1 (1) 0
Infection 0 1 (1) 0
Decreased appetite 9 (7) 2 (2) 0
Dehydration 0 1 (1) 0
Diabetic ketoacidosis 0 0 1 (1)
Hyperglycemia 1 (1) 0 1 (1)
Type I diabetes
mellitus
0 1 (1) 0
Laryngeal edema 0 0 1 (1)
Pneumonitis 2 (2) 2 (2) 0
Respiratory distress 0 1 (1) 0
Facial swelling 3 (2) 1 (1) 1 (1)
www.jco.org © 2016 by American Society of Clinical Oncology 3841
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Biomarker Analysis
When PD-L1 expression analyses were restricted to only
tumor cells, there was no statistically significant increase in the
probability of response for patients with positive ($ 1%) versus
negative (, 1%) tumors (P = .348, one-sided test). Conversely,
when immune cells were included in the scoring system,
a statistically significant increase in the probability of response
for positive ($ 1%) versus negative (, 1%) patients was ob-
served (P = .021, one-sided test). ORR in patients who were
PD-L1 positive by tumor and immune cell scoring was 22%,
whereas those who were negative had an ORR of 4% (Fig 3).
Similarly, statistically significant differences for PFS and OS
were observed when scoring took into account staining in both
tumor and immune cells (PFS: P = .008; OS: P = .008, one-sided
tests) but not tumor cells alone (PFS: P = .195; OS: P = .132,
one-sided tests). Median OS times for patients who were PD-L1
positive versus negative by tumor and immune cell scoring were
303 days and 151 days, respectively (Fig 3).
DISCUSSION
This study establishes the efficacy and safety of a fixed dose of
pembrolizumab (200 mg) administered once every 3 weeks in
patients with HNSCC. With an ORR of 18% by central imaging
vendor review, an ORR of 20% by investigator review, an OS of
8 months, and a DOR that was not reached, the clinical benefit
of pembrolizumab in biomarker-unselected patients with R/M
HNSCC was similar to that seen in the initial cohort of patients
who were PD-L1 positive (ORR, 18% by central imaging vendor
review; median OS, 13 months; median DOR, 53 weeks).24 The
response in this heavily pretreated population compares fa-
vorably with that observed with single-agent cetuximab (ORR,
13%; DOR, 4 months).27 In addition, median OS was on par
with the longest median survival reported in patients with
treatment-naive R/MHNSCC (10 months), which was achieved
with a combination of platinum, cetuximab, and fluorouracil
(EXTREME regimen),6 and similar to that observed with afa-
tinib in patients with previously treated R/M disease (7 months).28
In contrast to the significant toxicity observed with the EXTREME
regimen, pembrolizumab was well tolerated in this study. The
safety profile in the expansion cohort was consistent with the
safety profiles of pembrolizumab that were reported in
the initial HNSCC cohort and in studies in melanoma and
NSCLC.21,22,25
Approximately one half of all patients in this study with
HNSCC of the oropharynx had HPV-associated disease, which
has been associated with longer survival than non–HPV-
associated HNSCC.5 Similar to the initial HNSCC cohort of
the KEYNOTE-012 trial, a higher response to pembrolizumab
was observed in patients with HPV-associated versus non–HPV-
associated HNSCC.24 Of note, an ORR of 14% was consis-
tently observed in patients with HPV-negative disease in both
KEYNOTE-012 HNSCC cohorts, which suggests that those with
non–HPV-associated R/M HNSCC—a group with particularly
poor prognosis—may also benefit from pembrolizumab. This is
not surprising given the emerging evidence that supports the use
of PD-1–targeted therapies to treat both HPV-associated and
non–HPV-associated HNSCC.18,29 Although HPV-associated
and non–HPV-associated HNSCC differ in several ways, and the
mechanisms that lead to PD-L1 expression may differ between the
two, PD-L1 has been shown to be overexpressed in both settings.
Whether there is a difference between PD-L1 expression levels in
HNSCC on the basis of HPV association remains unclear given the
current literature.
A limitation of this study is the lack of a consistent method
used to determine HPV status. HPVassociation was determined by
Table 3. Antitumor Activity of Pembrolizumab (confirmed responses per RECIST v1.1, central imaging vendor review)
Response
Evaluation
All Patients
(N = 132)*
HPV Associated
(n = 28)
Non–HPV Associated
Total (n = 104)
Oropharynx HPV
Negative + Oral
Cavity, Hypopharynx,
and Larynx, All
Regardless of HPV
Status (n = 76)
All Other Tumor
Locations, Regardless
of HPV Status (n = 28)
No. (%) 95% CI No. (%) 95% CI No. (%) 95% CI No. (%) 95% CI No. (%) 95% CI
ORR 24 (18) 12 to 26 9 (32) 16 to 52 15 (14) 8 to 23 11 (15) 8 to 24 4 (14) 4 to 33
Best overall response
CR 4 (3) 1 to 8 3 (11) 2 to 28 1 (1) 0 to 5 1 (1) 0 to 71 0 (0) 0 to 12
PR 20 (15) 10 to 22 6 (21) 8 to 41 14 (14) 8 to 22 10 (13) 7 to 23 4 (14) 4 to 33
SD 26 (20) 13 to 28 4 (14) 4 to 33 22 (21) 14 to 30 19 (25) 16 to 36 3 (11) 2 to 28
Non-CR/Non-PD 1 (1) 0 to 4 0 (0) 0 to 12 1 (1) 0 to 5 1 (1) 0 to 7 0 (0) 0 to 12
PD 61 (46) 38 to 55 10 (36) 19 to 56 51 (49) 39 to 59 35 (46) 35 to 58 16 (57) 37 to 76
NA† 18 (14) 8 to 21 5 (17) 6 to 37 13 (13) 7 to 20 8 (11) 5 to 20 5 (18) 6 to 37
NE‡ 2 (2) 0.2 to 5 0 (0) 0 to 12 2 (2) 0.2 to 7 2 (3) 0.3 to 9 0 (0) 0 to 12
Abbreviations: AE, adverse event; CR, complete response; HPV, human papillomavirus; NA, not assessed; NE, not evaluable; ORR, overall response rate;
PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
*Includes patients who received one or more doses of pembrolizumab.
†No assessment as a result of PD (n = 11), AE (n = 3), death (n = 2), protocol violation (n = 1), and withdrawal by patient (n = 1).
‡Images were not of sufficient quality to be evaluable.
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the site investigator by using the method of their choice; p16
IHC was used by the majority of sites. Whereas p16 IHC is
a useful surrogate for HPV infection in oropharyngeal HNSCC,
it has limited utility outside of the oropharynx where HPV
is less prevalent.30,31 For that reason, patients with non-
oropharyngeal HNSCC were considered to be HPV-negative
regardless of p16 status. In addition, the number of patients
with HPV-associated disease in this study was substantially less
than the number with non–HPV-associated HNSCC. Response
by HPVassociation should be interpreted with these limitations
in mind.
On the basis of an evolving body of evidence in HNSCC
and other solid tumors that suggest PD-L1 expression on
tumor-infiltrating immune cells may contribute to clinical
outcome,32,33 two scoring systems were used to determine PD-L1
expression: one that analyzed expression on only tumor cells
and another that included both tumor and immune cells.
Although we did not independently determine the contribution
of each cell type, we have demonstrated that PD-L1 expression
on immune cells significantly contributes to the predictability
of response in HNSCC, as PD-L1 expression on tumor cells
alone was not significantly correlated with response.
Results from the current study indicate that the less fre-
quent, fixed dose of pembrolizumab is tolerable and provides
comparable antitumor activity with pembrolizumab adminis-
tered in a body weight–based dosing regimen. Patients responded
to pembrolizumab regardless of HPV status, and PD-L1 ex-
pression on tumor and immune cells was found to be associ-
ated with response. These findings support ongoing phase II
(KEYNOTE-055) and phase III (KEYNOTE-040 and KEYNOTE-
048) studies of the fixed-dose regimen in patients with advanced
HNSCC.
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Fig 2. Efficacy of pembrolizumab on the basis of RECIST (v1.1; Response Evaluation Criteria in Solid Tumors) by central imaging vendor review. (A)Maximum percentage
change from baseline in target lesions. Includes patients who had a comparable number of lesions between baseline and postbaseline scans (n = 96). (B) Treatment
exposure and response duration in responders (all responders, n = 24). (C andD) Kaplan-Meier estimates of (C) progression-free survival and (D) overall survival (all-patients-
as-treated population, N = 132). CR, complete response; PD, progressive disease; PR, partial response.
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